样式: 排序: IF: - GO 导出 标记为已读
-
Kidney Transplant of the Undocumented Immigrant: A Proposal Whose Benefits Outweigh the Status Quo Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-05-06 George N. Coritsidis, Adam Block, Isaac Pak, Rajkumar S. Pammal
An abstract is unavailable. This article is available as a PDF only.
-
Rates of Heart Failure with Preserved Ejection Fraction in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-05-06 Khalid Namoos, Cheng-Wei Huang, In-Lu Amy Liu, Janet S. Lee, David K. Yi, John J. Sim
An abstract is unavailable. This article is available as a PDF only.
-
Longitudinal plasma metabolome patterns and relation to kidney function and proteinuria in pediatric chronic kidney disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-05-06 Arthur M. Lee, Yunwen Xu, Jian Hu, Rui Xiao, Stephen R. Hooper, Erum A. Hartung, Josef Coresh, Eugene P. Rhee, Ramachandran S. Vasan, Paul L. Kimmel, Bradley A. Warady, Susan L. Furth, Michelle R. Denburg, on behalf of the CKD Biomarkers Consortium*
is a limited number of studies of longitudinal metabolomics, and virtually none in pediatric CKD. Methods The Chronic Kidney Disease in Children (CKiD) study is a multi-institutional, prospective cohort that enrolled children aged six-months to 16-years with estimated glomerular filtration rate (eGFR) 30-90ml/min/1.73m2. Untargeted metabolomics profiling was performed on plasma samples from the baseline
-
Genomic Testing in Patients with Kidney Failure of an Unknown Cause: a National Australian Study Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-05-03 Amali C. Mallawaarachchi, Lindsay Fowles, Louise Wardrop, Alasdair Wood, Rosie O’Shea, Erik Biros, Trudie Harris, Stephen I Alexander, Simon Bodek, Neil Boudville, Jo Burke, Leslie Burnett, Sarah Casauria, Steve Chadban, Aron Chakera, Sam Crafter, Pei Dai, Paul De Fazio, Randall Faull, Andrew Honda, Vanessa Huntley, Sadia Jahan, Kushani Jayasinghe, Matthew Jose, Anna Leaver, Mandi MacShane, Evanthia
rs of etiology. We aimed to determine the diagnostic utility of whole-genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods We prospectively recruited 100 participants who reached CKD stage 5 at 50 years of age and had an unknown cause of kidney failure after standard investigation. Clinically-accredited WGS was performed in this
-
Outpatient Nephrology Follow-Up after Community-Acquired Acute Kidney Injury among United States Veterans Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-26 Clarissa J. Diamantidis, Lindsay Zepel, Matthew L. Maciejewski, M. Alan Brookhart, C. Barrett Bowling, Virginia Wang
An abstract is unavailable. This article is available as a PDF only.
-
Utility of Blood Biomarkers to Predict Marrow Iron Stores in Children Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-30 Shilpa Sharma, Renata C. Pereira, Elizabeta Nemeth, Mark R. Hanudel, Joachim H. Ix, Isidro B. Salusky, Tomas Ganz
d standard) in this population with kidney failure who underwent bone biopsies. Methods: This cross-sectional study enrolled 71 clinically stable children and young adults receiving dialysis who underwent bone biopsy for chronic kidney disease-mineral bone disorder between 2007 through 2011. Bone biopsies were stained with Perls’ Prussian blue and independently interpreted by a pathologist blinded
-
Kinetics of Beta2-Microglobulin with Hemodiafiltration and High-Flux Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-23 Richard A. Ward, John T. Daugirdas
emodialysis. The impact of hemodiafiltration on beta-2-microglobulin levels was evaluated by modeling four randomized studies of hemodiafiltration vs. hemodialysis. The impact of residual kidney function on beta-2-microglobulin was tested by comparing results of previously reported measured data with model predictions. Results: In the low-flux and high-flux arms of the HEMO study, measured median
-
Time is Money: Protected Time for Fellow Education Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Alice M. Sheridan
An abstract is unavailable.
-
The Clinical Study of Kidney Stone Disease and the Value of Specificity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Alan C. Pao, Calyani Ganesan
An abstract is unavailable.
-
Did the SCORED Trial Get Extra Points for Kidney Outcomes? If So, It Is Not Obvious Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Nupur Mistry, George L. Bakris
An abstract is unavailable.
-
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-16 Robert A. Fletcher, William G. Herrington, Rajiv Agarwal, Kaitlin J. Mayne, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Natalie Staplin, David C. Wheeler, Glenn M. Chertow, Hiddo J. L. Heerspink, Brendon L. Neuen
An abstract is unavailable. This article is available as a PDF only.
-
Association of Inflammatory Bowel Disease with Incident Immunoglobulin A Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-11 Takashin Nakayama, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Norihiko Takeda, Akira Fukui, Takashi Yokoo, Hideo Yasunaga, Masaomi Nangaku, Kaori Hayashi
sing a large-scale epidemiological cohort. Methods We retrospectively analyzed 4,311,393 adults enrolled in the JMDC Claims Database (previously known as the Japan Medical Data Center database), a nationwide epidemiological database in Japan. The definitions of IgA nephropathy and inflammatory bowel disease (ulcerative colitis or Crohn’s disease) were based on International Classification of Diseases-10th
-
Calibration of Priority Points for Sensitization Status of Kidney Transplant Candidates in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-21 Jesse. D. Schold, Anat R. Tambur, Sumit Mohan, Bruce Kaplan
uld improve equity in access to transplantation for disadvantaged candidates. We sought to evaluate the effect of these weights using a contemporary cohort of adult US kidney transplant candidates. Methods We used the national Scientific Registry of Transplant Recipients to evaluate factors associated with sensitization using multivariable logistic models and rates of deceased donor transplantation
-
Nonlupus Full House Nephropathy: A Systematic Review Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-26 Martina Uzzo, Andreas Kronbichler, Federico Alberici, Ingeborg Bajema
h comparable outcomes.The identification of three pathogenetic categories provides further clues for a shared clinical and diagnostic approach to the disease. Background The presence of a full house pattern at immunofluorescence on kidney biopsy in a patient without clinical and laboratory features of systemic lupus erythematosus (SLE) has led to the descriptive term nonlupus full house nephropathy
-
Associations between Different Antivirals and Hospital acquired Acute Kidney Injury in Adults with Herpes Zoster Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-26 Ruqi Xu, Qi Gao, Yuping Zhang, Yuxin Lin, Yanqin Li, Licong Su, Shiyu Zhou, Yue Cao, Peiyan Gao, Pingping Li, Fan Luo, Ruixuan Chen, Xiaodong Zhang, Sheng Nie, Xin Xu, the CRDS study Investigators
China Renal Data System (CRDS). We identified and staged AKI using patient-level serum creatinine data according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria. We compared the relative risks of hospital acquired AKI among patients treated with different antivirals using Cox proportional hazards models. Results: Among 3273 patients, 1480 (45%), 681 (21%), 489 (15%) and 623 (19%) were
-
Clinical Outcomes after a Kidney Stone Event in Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-14 Ganesan, Calyani, Liu, Sai, Montez-Rath, Maria, Leppert, John T., Pao, Alan C.
No abstract available
-
How We Treat Primary Hyperoxaluria Type 1 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-18 Breeggemann, Matthew C., Harris, Peter C., Lieske, John C., Tasian, Gregory E., Wood, Kyle D.
No abstract available
-
The Future of the US Nephrology Workforce following the End of Affirmative Action Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-07 Deidra C. Crews
An abstract is unavailable.
-
KRT in Patients with AKI and Cirrhosis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-05 Sapna V. Shah, Mitra K. Nadim
An abstract is unavailable.
-
Different interdialytic intervals and cardiorespiratory fitness in patients undergoing hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-26 Eva Pella, Aristi Boulmpou, Afroditi Boutou, Marieta P. Theodorakopoulou, Nasra Haddad, Antonios Karpetas, Panagiotis Giamalis, Aikaterini Papagianni, Christodoulos E. Papadopoulos, Vassilios Vassilikos, Pantelis Sarafidis
ssessed with cardiopulmonary exercise testing (CPET) between the end of the 2-day and the 3-day interdialytic interval. Methods: A total of 28 hemodialysis patients, randomized in two different sequences of evaluation underwent CPET and spirometry examination at the end of the 2-day and the 3-day intervals. The primary outcome was the difference in oxygen uptake at peak exercise [VO2peak(ml/kg/min)]
-
Cover Image Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-01 Bakis, Hugo
No abstract available
-
-
Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-29 Xiaofan Hu, Jing Xu, Wei Wang, Lili Liu, Yuanmeng Jing, Chenni Gao, Xialian Yu, Yi Li, Li Lin, Jun Tong, Qinjie Weng, Xiaoxia Pan, Wen Zhang, Hong Ren, Guisen Li, Krzysztof Kiryluk, Nan Chen, Jingyuan Xie
of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥25 ml/min per 1.73 m2. The combined risk score was calculated by combining the genetic risk score with PLA2R ELISA antibody titers. The primary end point was kidney disease progression defined as a 50% reduction in eGFR or kidney failure. Cox proportional hazard regression analysis and C-statistics were
-
Combined Serologic and Genetic Risk Score and Prognostication of PLA2R-Associated Membranous Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-29 Hu, Xiaofan, Xu, Jing, Wang, Wei, Liu, Lili, Jing, Yuanmeng, Gao, Chenni, Yu, Xialian, Li, Yi, Lin, Li, Tong, Jun, Weng, Qinjie, Pan, Xiaoxia, Zhang, Wen, Ren, Hong, Li, Guisen, Kiryluk, Krzysztof, Chen, Nan, Xie, Jingyuan
Introduction: The aim of this study was to test whether a combined risk score based on genetic risk and serology can improve the prediction of kidney failure in PLA2R-associated primary membranous nephropathy. Methods: We performed a retrospective analysis of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥ 25ml/min/1.73m2. The combined risk score was
-
Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients: A Randomized Placebo-Controlled Clinical Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-27 Line A. Mortensen, Bente Jespersen, Anne Sophie L. Helligsoe, Birgitte Tougaard, Donata Cibulskyte-Ninkovic, Martin Egfjord, Lene Boesby, Niels Marcussen, Kirsten Madsen, Boye L. Jensen, Inge Petersen, Claus Bistrup, Helle C. Thiesson
ey transplant patients treated with calcineurin inhibitors. Methods: Randomized, placebo-controlled, double blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for three years. Glomerular filtration rate was measured along with proteinuria and kidney fibrosis. The primary endpoint was change in measured glomerular filtration
-
Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-26 Thomas Bais, Paul Geertsema, Martine G.E. Knol, Maatje D.A. van Gastel, Robbert J. de Haas, Esther Meijer, Ron T. Gansevoort, on behalf of the DIPAK Consortium
ease cohort. Methods Included were patients with ≥1 height-adjusted total kidney volume (HtTKV) measurement and ≥3 eGFR values during ≥1-year follow-up. Mayo HtTKV class stability, kidney growth rates, and eGFR decline rates were calculated. The observed eGFR decline was compared with predictions from the Mayo Clinic future eGFR equation. The future eGFR prediction equation was also tested for nonlinear
-
Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-22 Gillian Divard, Olivier Aubert, Charlotte Debiais-Deschamp, Marc Raynaud, Valentin Goutaudier, Marta Sablik, Caroline Sayeg, Christophe Legendre, Julie Obert, Dany Anglicheau, Carmen Lefaucheur, Alexandre Loupy
and safety after conversion to belatacept. Methods We prospectively enrolled 311 kidney transplant recipients from 2007 to 2020 from two referral centers, converted from CNI to belatacept after transplant according to a prespecified protocol. Patients were matched at the time of conversion to patients maintained with CNIs, using optimal matching. The primary end point was death-censored allograft survival
-
Trends in Automated Peritoneal Dialysis Prescriptions in a Large Dialysis Organization in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-19 Harold E. Giles, Vidhya Parameswaran, Rachel Lasky, Linda Ficociello, Claudy Mullon, Dinesh K. Chatoth, Michael Kraus, Michael S. Anger
. The present analysis aimed to assess variations in PD prescriptions among incident automated PD (APD) patients who remain on PD for 120+ days. Methods: This retrospective analysis examined data from patients within a large dialysis organization that initiated PD with APD between 2015 and 2019. PD prescription data was described by calendar year, timing of PD, and residual renal function categories
-
RNA Interference as a Therapeutic Approach for Managing Hypertension Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Jia Wei Tan, Vivek Bhalla
An abstract is unavailable. This article is available as a PDF only.
-
Fructokinase Inhibition to Prevent Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Ducloux, Didier
No abstract available
-
Dialysate Sodium Lowering in Maintenance Hemodialysis A Randomized Clinical Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Dana C. Miskulin, Hocine Tighiouart, Caroline M. Hsu, Daniel E. Weiner
to 140 mEq/L in low arm participants. The primary outcome was intradialytic hypotension (IDH). Secondary outcomes included dialysis disequilibrium symptoms, ER visits/hospitalizations, interdialytic weight gain, blood pressure (BP). Longitudinal changes across arms were analyzed using linear mixed regression. Results: Treatment to dialysate sodium 135 vs. 138 mEq/L was not associated with a difference
-
Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-12 Kumaran Arivoli, Autumn N. Valicevic, Mary K. Oerline, Ryan S. Hsi, Sanjeevkumar R. Patel, John M. Hollingsworth, Vahakn B. Shahinian
cians. This study aimed to evaluate the association between preventive pharmacological therapy (thiazide diuretics, alkali therapy, and uric acid–lowering medications) and clinically significant urinary stone disease recurrence. Methods Using data from the Veterans Health Administration, adults with an index episode of urinary stone disease from 2012 through 2019 and at least one urinary abnormality
-
Should Transplant Nephrology pursue recognition from the Accreditation Council for Graduate Medical Education (ACGME)? Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-06 Neeraj Singh, Prince M Anand, Gaurav Gupta, Deirdre Sawinski, Oren Fix, Deborah Adey, Enver Akalin, Carlos Zayas, Darshana Dadhania, Mona Doshi, Diane Cibrik, Mallika Gupta, Ronald Parsons, Nicolae Leca, Rowena Delos Santos, Beatrice P Concepcion, Angie G Nishio Lucar, Song Ong, Vikas Srinivasan Sridhar, Sandesh Parajuli, Mareena Zachariah, Shikha Mehta, Karim Soliman, Saed Shawar, Syed Ali Husain
understand immunology and organ rejection, have familiarity with peri-operative complications, and have the ability to manage the long-term effects of chronic immunosuppression. This skill set at the intersection of multiple disciplines necessitates additional training in Transplant Nephrology. Currently, there are more than 250,000 patients with a functioning kidney allograft and over 100,000 waitlisted
-
Embracing Complexity to Better Serve Pediatric Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-05 Lindsey M. Maclay, S. Ali Husain
An abstract is unavailable.
-
-
-
Pregnancy in Patients Receiving Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-29 Ghada Ankawi, Nishanta Tangirala, Shilpanjali Jesudason, Michelle A. Hladunewich
ntil after kidney transplantation. Pregnancy rates in women with advanced kidney failure or receiving dialysis remain low, and despite the improved outcomes in recent years, these pregnancies remain high risk for both mother and baby with high rates of preterm birth due to both maternal and fetal complications. However, with increased experience and advances in models of care, this paradigm may be
-
Closure of Dialysis Clinics in the US in 2021-2023 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Kamyar Kalantar-Zadeh, Dawn P. Edwards, David Henner, Daniel L Landry, Donald A Molony, Preethi Yerram, on behalf of the Medical Advisory Council of the National Forum of ESRD Networks
An abstract is unavailable. This article is available as a PDF only.
-
Effects of Vitamin D3 Supplementation on Incident Fractures by eGFR in VITAL Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Hsu, Simon, Zelnick, Leila R., Buring, Julie E., Chou, Sharon H., Cook, Nancy R., D’Agostino, Denise, Hoofnagle, Andrew N., LeBoff, Meryl S., Lee, I-Min, Limonte, Christine P., Sesso, Howard D., Manson, JoAnn E., de Boer, Ian H.
No abstract available
-
Moving toward Racial Equity in Preemptive Listing for Kidney Transplant in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 McElroy, Lisa M., Schold, Jesse D.
No abstract available
-
Mechanistic Basis for Intradialytic Hypertension with Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Hecking, Manfred, Mussnig, Sebastian, Chazot, Charles
No abstract available
-
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-26 Vikas S. Sridhar, Deepak L. Bhatt, Ayodele Odutayo, Michael Szarek, Michael J. Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg, David Z.I. Cherney
f eGFR laboratory data and case report forms had not been completed. This resulted in a small number of kidney composite events and a nominal effect of sotagliflozin versus placebo on this outcome. This exploratory analysis uses laboratory eGFR data, regardless of case report form completion, to assess the effects of sotagliflozin on the predefined kidney composite end point in the SCORED trial and
-
Effects of Vitamin D3 Supplementation on Incident Fractures by eGFR in VITAL Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Simon Hsu, Leila R. Zelnick, Julie E. Buring, Sharon H. Chou, Nancy R. Cook, Denise D'Agostino, Andrew N. Hoofnagle, Meryl S. LeBoff, I-Min Lee, Christine P. Limonte, Howard D. Sesso, JoAnn E. Manson, Ian H. de Boer
An abstract is unavailable.
-
Mechanistic Basis for Intradialytic Hypertension with Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Manfred Hecking, Sebastian Mussnig, Charles Chazot
An abstract is unavailable.
-
Moving toward Racial Equity in Preemptive Listing for Kidney Transplant in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 McElroy, Lisa M., Schold, Jesse D.
No abstract available
-
Reverse Phenotypes of Patients with Genetically Confirmed Liddle Syndrome Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Jeff Granhøj, Thomas K. Nøhr, Gitte R. Hinrichs, Maria Rasmussen, Per Svenningsen
henotypic spectrum of genetically confirmed Liddle syndrome is unknown, and some patients may remain undiagnosed and at risk of inefficient treatment. In this study, we used a reverse phenotyping approach to investigate the Liddle syndrome phenotypic spectrum and genotype–phenotype correlations. Methods Pubmed, Embase, Scopus, and the Human Gene Mutation Database were searched for articles reporting
-
Kidney after Liver Transplantation for All: Are You Kidneying Me? Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Abhishek Kumar, Hani M. Wadei
An abstract is unavailable.
-
Closure of Dialysis Clinics in the United States in 2021–2023 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Kalantar-Zadeh, Kamyar, Edwards, Dawn P., Henner, David, Landry, Daniel L., Molony, Donald A., Yerram, Preethi, on behalf of the Medical Advisory Council of the National Forum of ESRD Networks
No abstract available
-
Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Sean J. Barbour, Rosanna Coppo, Lee Er, Evangeline Pillebout, Maria Luisa Russo, Charles E. Alpers, Agnes B. Fogo, Franco Ferrario, J. Charles Jennette, Ian S.D. Roberts, H. Terence Cook, Jie Ding, Baige Su, Xuhui Zhong, Fernando C. Fervenza, Ladan Zand, Licia Peruzzi, Laura Lucchetti, Ritsuko Katafuchi, Yuko Shima, Norishige Yoshikawa, Daisuke Ichikawa, Yusuke Suzuki, Luisa Murer, Robert J. Wyatt
ts. Methods Biopsies from 262 children and 99 adults with IgA vasculitis nephritis (N=361) from 23 centers in North America, Europe, and Asia were independently scored by three pathologists. MEST-C scores were assessed for correlation with eGFR/proteinuria at biopsy. Because most patients (N=309, 86%) received immunosuppression, risk factors for outcomes were evaluated in this group using latent class
-
Evaluation and Measurement Properties of a Patient-Reported Experience Measure for Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Matthew B. Rivara, David K. Prince, Kerstin K. Leuther, Wael F. Hussein, Rajnish Mehrotra, Todd Edwards, Brigitte Schiller, Donald L. Patrick
thods Using mail and telephone survey modalities, we approached 1372 patients treated with peritoneal dialysis or home hemodialysis for participation. Using the results from completed surveys, we evaluated item calibration by assessing item floor and ceiling effects. We tested three sets of composite scores and used factor analysis to assess model fit for each. We evaluated associations of composite
-
Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial: A: Post Hoc: Analysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Shweta Bansal, Robert Boucher, Jincheng Shen, Guo Wei, Glenn M. Chertow, Paul K. Whelton, William C. Cushman, Alfred K. Cheung, Srinivasan Beddhu, on behalf of SPRINT
SPRINT was a randomized, controlled trial of 9361 participants comparing the effects of intensive (systolic BP target <120 mm Hg) versus standard (systolic BP target <140 mm Hg) BP control on a primary composite cardiovascular end point in participants aged 50 years or older with systolic BP of 130–180 mm Hg. In time-varying multivariable Cox analyses, we assessed hazard ratios (HRs) of cardiovascular
-
Effect of Remote and Virtual Technology on Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-22 Susie Q. Lew, Sabrina Milan Manani, Claudio Ronco, Mitchell H. Rosner, James A. Sloand
expected accelerant for telehealth use in the United States. Within nephrology, remote patient monitoring has most often been applied to the care of patients on home dialysis modalities. The effect that remote and virtual technologies have on home dialysis patients, telehealth and health care disparities, and health care providers' workflow changes are discussed here. Moreover, the future use of remote
-
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-15 Jonathan Barratt, Adrian Liew, See Cheng Yeo, Anders Fernström, Sean J. Barbour, C. John Sperati, Russell Villanueva, Ming-Ju Wu, Dazhe Wang, Anna Borodovsky, Prajakta Badri, Elena Yureneva, Ishir Bhan, Daniel Cattran, on behalf of the Cemdisiran Phase 2 Study Investigators and Collaborators
Cemdisiran is an investigational RNA interference therapeutic that suppresses hepatic production of complement component 5 (C5), thereby potentially reducing proteinuria in IgA nephropathy. We evaluated the efficacy and safety of cemdisiran in adult patients with IgA nephropathy at high risk of kidney disease progression. Methods In this phase 2, 36-week, double-blind study, adult patients with IgA
-
Home Dialysis in Patients with Cardiovascular Diseases Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-10 Reaves, Allison C., Weiner, Daniel E., Sarnak, Mark J.
Kidney failure with replacement therapy and cardiovascular disease are frequently comorbid. In patients with kidney failure with replacement therapy, cardiovascular disease is a major contributor to morbidity and mortality. Conventional thrice-weekly in-center dialysis confers risk factors for cardiovascular disease including acute hemodynamic fluctuations and rapid shifts in volume and solute concentration
-
Improving Waitlist Eligibility by Race and Ethnicity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-12 Wendy Rodgers
An abstract is unavailable.
-
Hemoadsorption Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-15 Bellomo, R, Mehta, RL, Forni, LG, Zarbock, A, Ostermann, M, Ronco, C, on behalf of the Acute Disease Quality Initiative Hemoadsorption Working Group
No abstract available
-
Improving Waitlist Eligibility by Race and Ethnicity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-12 Rodgers, Wendy
No abstract available
-
Complications of Peritoneal Dialysis Part I: Mechanical Complications Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Xin Bo Justin Cheng, Joanne Bargman
inuation of therapy. Timely diagnosis and resolution are required to minimize preventable modality change to hemodialysis. This review covers mechanical complications, including leaks, PD hydrothorax, hernias, dialysate flow problems, PD-related pain, and changes in respiratory mechanics. Most mechanical complications occur early, either as a result of PD catheter insertion or the introduction of dialysate
-
Protected Time for Program Administration among Nephrology Program Leadership in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Christina M. Yuan, Brian Y. Young, Maura A. Watson, Amy N. Sussman
n anonymous, online survey of all US adult nephrology program directors (March 2023), who forwarded core faculty/associate program director (APD) surveys. The questions included protected time in 2022–2023 and 2021–2022, whether it was sufficient, estimated time needed, and two validated single-item burnout measures (emotional exhaustion and depersonalization). The analysis was descriptive. Results
-
From Home to Wearable Hemodialysis: Barriers, Progress, and Opportunities Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Matthew B. Rivara, Jonathan Himmelfarb
present barriers for more widespread adoption by a larger proportion of individuals with kidney failure. These limitations include device weight and bulk, ergonomics considerations, technical complexity, vascular access challenges, and limited remote patient monitoring. Recent years have witnessed a resurgence in research and development of prototype wearable kidney replacement devices incorporating